Clinical relapses and adverse events after treatment with rituximab in the acute phase of autoimmune TTP, in reports involving 10 or more patients
| Series (year) . | Clinical relapse (%) . | Time to relapse, median (range) . | Clinical RFS* (months), median (range) . | Serious adverse events . |
|---|---|---|---|---|
| Scully et al (2007)94 | 0 | — | 10 (1-33 mo) | 1 fatal pneumonia, 1 morbilliform rash |
| Jasti et al (2008)90 | 8 | 23 mo | 48.5 (1-79 mo) | 1 VZV transverse myelitis and encephalitis |
| Ling et al (2009)91 | 0 | — | 24 (13-84 mo) | 0 |
| de la Rubia et al (2010)92 | 12.5 | 29 mo (7-29 mo) | 30 (7.5-64 mo) | 0 |
| Scully et al (2011)89 | 10 | 27 mo (17-31 mo) | ≥12 | 0 |
| Froissart et al (2012)82 | 14 | 24 mo (20-36 mo) | 33 ± 17.4 | 0 |
| Page et al (2016)93 | 12.5* | 2.5 and 9.9 y | — | 0 |
| Series (year) . | Clinical relapse (%) . | Time to relapse, median (range) . | Clinical RFS* (months), median (range) . | Serious adverse events . |
|---|---|---|---|---|
| Scully et al (2007)94 | 0 | — | 10 (1-33 mo) | 1 fatal pneumonia, 1 morbilliform rash |
| Jasti et al (2008)90 | 8 | 23 mo | 48.5 (1-79 mo) | 1 VZV transverse myelitis and encephalitis |
| Ling et al (2009)91 | 0 | — | 24 (13-84 mo) | 0 |
| de la Rubia et al (2010)92 | 12.5 | 29 mo (7-29 mo) | 30 (7.5-64 mo) | 0 |
| Scully et al (2011)89 | 10 | 27 mo (17-31 mo) | ≥12 | 0 |
| Froissart et al (2012)82 | 14 | 24 mo (20-36 mo) | 33 ± 17.4 | 0 |
| Page et al (2016)93 | 12.5* | 2.5 and 9.9 y | — | 0 |
RFS, relapse-free survival; VZV, varicella zoster virus.
*Two relapses.